Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...

Mean absorption is shown ... and remained relatively constant in Norgen's cf-DNA/cf-RNA Preservative Tubes. Image Credit: Norgen Biotek Corporation Figure 4. Prevent cell lysis and the release ...

The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...

New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...

Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward ...

The new technology, developed by a team at the Ulsan National Institute of Science and Technology (UNIST), identifies ...

TFE3 fusion proteins are the oncogenic drivers of translocation renal cell carcinoma but their mechanism of action remains ...

Yale scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related ...

The last week’s events in Queensland won’t have assuaged any fears over planning for the biggest show on earth.

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated ...